TABLE 2.
AST of Corynebacterium spp. isolated between 2006 and 2015
| Yr of isolation (no. of isolates) | CBPa | Sample origin | Susceptible isolates (%)b
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ERY | GEN | PEN | TET | VAN | CIP | CLI | LZD | RIF | |||
| 2006–2010 (26) | CLSI | Orthopedic | 35 | 85 | 65 | 100 | 100 | ND | ND | ND | ND |
| 2011–2015 (36) | EUCAST | Orthopedic | ND | 72 | 28 | 81 | 100 | 44 | 6 | 100c | 82c |
| 2006–2010 (36) | CLSI | Blood culture | 22 | 64 | 47 | 92 | 100 | ND | ND | ND | ND |
| 2011–2015 (28) | EUCAST | Blood culture | ND | 61 | 29 | 78 | 100 | 29 | 19 | 100d | 88d |
a
AST was performed by disc diffusion. Clinical breakpoints (CBP) from CLSI (19) were applied from 2006 to 2010, and CBP from EUCAST (20) were applied from 2011 to 2015.
b
ERY, erythromycin; GEN, gentamicin; PEN, penicillin; TET, tetracycline; VAN, vancomycin; CIP, ciprofloxacin; CLI, clindamycin; LZD, linezolid; RIF, rifampin; ND, not determined.
c
AST data for linezolid and rifampin were available for 12 and 17 isolates, respectively.
d
AST data for linezolid and rifampin were available for 12 and 17 isolates, respectively.